Next Article in Journal
How Severe Anaemia Might Influence the Risk of Invasive Bacterial Infections in African Children
Previous Article in Journal
A Novel Cis-Acting RNA Structural Element Embedded in the Core Coding Region of the Hepatitis C Virus Genome Directs Internal Translation Initiation of the Overlapping Core+1 ORF
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 18
10.3390/ijms21186975
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors

Int. J. Mol. Sci. 2020, 21(18), 6975; https://doi.org/10.3390/ijms21186975
by Azadeh Amirnasr, Stefan Sleijfer and Erik A. C. Wiemer *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2020, 21(18), 6975; https://doi.org/10.3390/ijms21186975
Submission received: 2 September 2020 / Revised: 14 September 2020 / Accepted: 16 September 2020 / Published: 22 September 2020
(This article belongs to the Section Molecular Oncology)

Round 1

Reviewer 1 Report

Thank you for giving me the opportunity to read this paper. It is interesting review that has the goal to elucidate the role of non-coding RNAs in Gastrointestinal Stromal Tumor. 

I think that the authors have reached their goal. 

I found only few tipying errors (i.e. ANO1 protein at line 33 is written without -, whereas at line 91 is reported as ANO-1).

However, in my opinion this is an interesting review for IJMS readership.

Author Response

Reply: We thank the reviewer for the positive remarks and for pointing out an inconsistency in the ANO1 notation. ANO1 (or DOG1) is the correct designation for this gene, we made sure this is consistently used in the revised manuscript.

Author Response File: Author Response.pdf

Reviewer 2 Report

In my opinion, the overall level of the paper is very good structured: it is well written and several important considerations are highlighted. The discussion sections provide useful information for the readers and the conclusions appear rationale, emphasizing the potential clinical applications of MiRNA or lncRNAs in GIST patients that have developed (multi)drug resistance

 

Minor comment:

  • references are not complete, there are several recently significant published papers on in this topic

Author Response

Reply: We thank the reviewer for pointing out that we missed literature of relevance for the topic of our review.  Although the reviewer does not mention specific publications, we screened the recent literature and included the following 4 publications in our revised manuscript.

  1. A very recent publication by Gyvyte U. et al. (Int J Mol Sci 2020, 21(14): 5151-) that reports on the functional roles of miR-375-3p and miR-200b-3p both miRNAs that are found downregulated in GIST.
  2. Two publications that profiled WT GIST in addition to mutant GIST by Pantaleo, M.A. et al. (Epigenomics 2016, 8(10): 1347- ) and Kelly, L. et al. (PLOS ONE 2013, 8(5): e64102).
  3. We now also refer to the paper of Bachet, J-B. et al. (PLOS ONE 2013, 8(4): e61103) who describe that gene expression patterns, including miRNA expression patterns, differ depending on the homozygous/heterozygous/hemizygous KIT mutational status and/or the specific nature of some KIT mutations.

We discuss these publications in the text, included them in the tables when appropriate and made sure they appear in the reference list. Please see the specific changes made to the manuscript in the manuscript text that highlights the changes in red. We believe we have sufficiently addressed this minor comment of the reviewer and now present a comprehensive review.

Author Response File: Author Response.pdf

Back to TopTop